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ess: ogat@df7.so-net.neSummary Goals of effective management of patients with chronic obstructive
pulmonary disease (COPD) include relieving their symptoms and improving their
health status. We examined how such patient reported outcomes would change
longitudinally in comparison to physiological outcomes in COPD.
One hundred thirty-seven male outpatients with stable COPD were recruited for
the study. The subjects health status was evaluated using the St. George’s
Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire
(CRQ). Their dyspnoea using the modified Medical Research Council (MRC) scale and
their psychological status using the Hospital Anxiety and Depression Scale (HADS)
were assessed upon entry and every 6 months thereafter over a 5-year period.
Pulmonary function and exercise capacity as evaluated by peak oxygen uptake ð _VO2 Þ
on progressive cycle ergometry were also followed over the same time.
Using mixed effects models to estimate the slopes for the changes, scores on the
SGRQ, the CRQ, the MRC and the HADS worsened in a statistically significant manner
over time. However, changes only weakly correlated with changes in forced
expiratory volume in 1 s (FEV1) and peak _VO2 :
We demonstrated that although changes in pulmonary function and exercise
capacity are well known in patients with COPD, patient reported outcomes such as
health status, dyspnoea and psychological status also deteriorated significantly over
time. In addition, deteriorations in patient reported outcomes only weakly
correlated to changes in physiological indices. To capture the overall deteriorationElsevier Ltd. All rights reserved.
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Changes in patient reported outcomes in COPD 147of COPD from the subjective viewpoints of the patients, patient reported outcomes
should be followed separately from physiological outcomes.
& 2006 Elsevier Ltd. All rights reserved.Introduction
The goals of effective management of patients with
stable chronic obstructive pulmonary disease
(COPD) include relieving their symptoms and
improving their health status, since none of the
existing pharmacological medications for COPD has
been shown to modify disease progression.1 How-
ever, in comparison to physiological changes in
pulmonary function, which is the hallmark of this
disease, the progression of patient reported out-
comes over time has been examined less fre-
quently. Since the traditional test of pulmonary
function as assessed by the forced expiratory
volume in 1 s (FEV1) does not necessarily correlate
strongly with patient reported clinical outcomes
such as health status, dyspnoea or psychological
status,2–4 a separate follow-up survey is important
to capture the overall deterioration in COPD from
the viewpoint of patients themselves.
Understanding the composition of patient re-
ported outcomes versus physician centered physio-
logical outcomes in COPD is indispensable, because
patients and physicians do not always share view-
points on what is important in this disease. As both
types of outcomes reflect complementary aspects
during the long-term follow-up of COPD, their
assessments will enable clinicians to evaluate the
overall effectiveness of the management of this
disease.
In analyzing longitudinal data, how to deal with
dropouts who withdraw from follow-up is a pro-
blem, because high numbers of dropouts are
reported in COPD clinical trials. For example, in
the Inhaled Steroids in Obstructive Lung Disease
(ISOLDE) study, 46.5% of the patients dropped out
at 3 years.5 Calverley et al.6 reported that losing
these patients from the final analysis can reduce
the power of the study to achieve its primary
endpoint as discontinued subjects were those with
the most rapidly deteriorating health status or
pulmonary function. Therefore, we attempted to
analyze longitudinal data in patients with COPD and
asthma, including dropouts.7–10
We followed longitudinal changes in physiological
outcomes and patient reported outcomes of health
status, dyspnoea and psychological status over 5
years in patients with COPD, and partly elsewhere
reported the physiological deteriorations in exer-cise capacity and pulmonary function.7 We hy-
pothesized that both types of outcomes would
deteriorate over time, but that their correlations
would be weak. Therefore, in the present observa-
tional study, we analyzed the 5–year longitudinal
changes in patient reported outcomes in patients
with COPD, and compared them with changes in
physician centered physiological outcomes.Methods
Subjects
We recruited 137 consecutive male outpatients
with moderate to very severe COPD between
September 1995 and April 1997, as previously
reported.7 Entry criteria included: (1) a smoking
history of more than 20 pack-years; (2) maximal
FEV1/forced vital capacity ratio of less than 0.7 and
postbronchodilator FEV1 of less than 80% of the
predicted normal; (3) regular attendance over 6
months; (4) no COPD exacerbations over the
preceding 6 weeks; and (5) no uncontrolled
comorbidities. Clinical measurements were evalu-
ated on the same day. COPD patients meeting entry
criteria were asked to have their clinical outcomes
evaluated at entry and every 6 months thereafter
over a 5–year period.7 When an exacerbation of
COPD requiring a change in treatment occurred
within 4 weeks of a reassessment day, the evalua-
tion was postponed for at least 4 weeks until the
patient recovered. The present study was per-
formed as part of our standard outpatient treat-
ment and care, and verbal informed consent was
obtained from all patients.Patient reported outcomes
Health status was measured using the disease-specific
measurements: the St. George’s Respiratory Ques-
tionnaire (SGRQ)11 and the Chronic Respiratory
Disease Questionnaire (CRQ)12; their Japanese ver-
sions have been previously validated.3 On the SGRQ,
3 components: symptoms, activity and impacts, and
the total scores were calculated, ranging from 0 to
100. On the CRQ, the patients rated 20 items on a
seven-point scale, and the 4 domains of dyspnoea,
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the total scores, were calculated as the average of
the sum. Increases in the scores reflect worsening of
health status on the SGRQ, and the opposite holds
true on the CRQ. A change in the SGRQ score of 4
units is consistent with a minimum clinically impor-
tant difference (MCID) for the patient,13 and with
respect to the CRQ, a change in the score of 0.5 units
is considered to be the MCID.14
Dyspnoea was evaluated using the Japanese
version of the modified Medical Research Council
(MRC) dyspnoea scale,4,15 which is a 5–point scale
based on degrees of various physical activities that
precipitate dyspnoea. Higher scores indicate worse
dyspnoea on the MRC.
Psychological status or mood was evaluated using
the Japanese version of the Hospital Anxiety and
Depression Scale (HADS),3,16 which consists of 14
items, 7 for anxiety and 7 for depression. Each item
is scored from 0 to 3, where a score of 3 represents
a state corresponding to the worst anxiety or
depression. The sum of these items produces 2
subscales ranging from 0 to 21.
Physiological outcomes
Pulmonary function tests were performed as pre-
viously described.7 Subjects underwent spirome-
try17 before and at 15 and 60min after inhaling
salbutamol (400 mg) and ipratropium bromide
(80 mg) using a metered-dose inhaler with a spacer
device. Predicted values were provided by the
Japan Society of Chest Diseases.18
Exercise capacity was evaluated using symptom-
limited progressive cycle ergometry, which was
performed 60min after bronchodilator inhalation
on a calibrated, electrically braked cycle erg-
ometer.7 Peak oxygen uptake ð _VO2Þ was calculated
as the highest level reached during exercise, and
was used as an index of exercise capacity.
Follow-up data
Among the 137 COPD patients enrolled, 72 patients
attended the last 5–year evaluation, and only one
patient was unavailable for follow-up. Twenty-five
patients died during the 5–year period, 36 patients
dropped out of the study due to an inability to
attend the hospital for various reasons, and 3
patients skipped the last appointment.
Statistical analysis
The results are expressed as means7SE, unless
otherwise stated. Mixed effects models for theslopes were used to estimate longitudinal changes
in the clinical parameters7,8 using Statistical
Analysis System PROC MIXED software.19 In these
analyses, the covariates included age and smoking
status as fixed effects, whereas time was entered
as a random effect.7 By performing these analyses,
all the data from the 137 patients entered in the
present study were included and analyzed. Bivari-
ate relationships between the slope changes were
analyzed by Pearson’s correlation coefficient tests.
To compare the responsiveness between the SGRQ
and the CRQ, two widely used responsiveness
indices of the effect size and the standardized
response mean were evaluated.20–22 The former
indicates the ratio of the mean change in the score
to the SD of the baseline scores. The latter indicates
the ratio of the mean change in the score to the SD
of that change. Comparisons of baseline data and
annual changes between survivors and non-survi-
vors were performed with an unpaired t-test. P-
values less than 0.05 were considered to be
statistically significant.Results
Patient characteristics
Baseline characteristics for 137 male patients
examined are presented in Table 1. The average
age was 69.070.6 years. At baseline, 103 patients
were former smokers and 34 were current smokers.
Their postbronchodilator FEV1 was 45.971.3%
predicted.
Longitudinal changes in clinical outcomes
Changes in health status, dyspnoea, psychological
status and airflow limitation are shown in Fig. 1 in
45 patients with COPD who had complete data sets
of these outcomes with no missing data every 6
months over 5 years. These results enable us to
compare individual changes in each measurement.
Health status evaluated by the SGRQ and the CRQ
total scores, and dyspnoea by the MRC scores
deteriorated more prominently than the percen-
tage of the predicted postbronchodilator FEV1
(%FEV1). Although psychological status evaluated
by the HADS scores also tented to deteriorate,
these deteriorations were not as prominent.
Results from the mixed effects models for the
slopes of the longitudinal changes in the clinical
parameters in all the 137 patients with COPD are
presented in Table 1. Regarding health status, the
activity and impact components, and total scores
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Table 1 Baseline data and annual changes in 137 patients with COPD.
Characteristic Baseline data Annual change (/year) P values
Age, years 69.070.6
SGRQ symptoms (0–100) 52.971.6 0.8370.43 0.054
SGRQ activity (0–100) 43.171.8 1.8370.39 o0.0001
SGRQ impact (0–100) 24.371.4 2.2470.37 o0.0001
SGRQ total (0–100) 36.271.4 1.8770.34 o0.0001
CRQ dyspnoea (1–7) 5.2870.09 0.1070.02 o0.0001
CRQ fatigue (1–7) 5.0270.11 0.1270.03 o0.0001
CRQ emotional function (1–7) 5.6870.08 0.1370.02 o0.0001
CRQ mastery (1–7) 5.5170.09 0.0870.02 0.0022
CRQ total (1–7) 5.3770.08 0.1270.02 o0.0001
MRC (0–4) 1.170.1 0.1470.02 o0.0001
HADS anxiety (0–21) 4.770.3 0.1670.08 0.046
HADS depression (0–21) 3.970.3 0.1770.07 0.023
Postbronchodilator FEV1, L 1.2270.04 0.025470.0059 o0.0001
Postbronchodilator FEV1, %pred 45.971.3 0.970.2 0.0001
Peak _VO2 mL/min/kg 14.870.3 0.570.1 o0.0001
Data are presented as mean7SE. Numbers in parentheses indicate theoretical score ranges.
Changes in patient reported outcomes in COPD 149on the SGRQ all showed significant deterioration
ðPo0:0001Þ, although only the change in the
symptoms component score did not reach a
statistically significant difference ðP ¼ 0:054Þ. With
respect to the CRQ, all 4 domains and total scores
showed statistically significant deterioration. The
mean annual change in the health status scores was
1.87 units/year from the SGRQ total score, and
0.12 units/year from the CRQ total score. There-
fore, the SGRQ total score took 2.14 years to
deteriorate by a MCID of 4 units, as compared to
4.17 years that the CRQ total score took to
decrease by a MCID of 0.5 units.
With regard to responsiveness between baseline
and 5–year evaluations about the abovementioned
45 patients with COPD (Fig. 1), the effect size and
the standardized response mean were 0.65 and
0.66 on the SGRQ, and 0.57 and 0.69 on the CRQ.
Dyspnoea evaluated by the MRC deteriorated
significantly at 0.1470.02 units/year ðPo0:0001Þ.
Regarding psychological status, both anxiety and
depression scores on the HADS also increased
significantly by mean changes of 0.16 units/year
ðP ¼ 0:046Þ and 0.17 units/year ðP ¼ 0:023Þ, respec-
tively; however, their statistical significances were
weaker than the changes in health status and
dyspnoea.
Changes in physiological outcomes are shown in
Table 1. Airflow limitation evaluated by post-
bronchodilator FEV1 and %FEV1 decreased over
time at a rate of 25:4 5:9mL=year ðPo0:0001Þ
and 0:9 0:2% pred/year ðP ¼ 0:0001Þ, respec-
tively. Exercise capacity expressed by peak _VO2
deteriorated at a rate of 0:5 0:1mL=min =
kg=year ðPo0:0001Þ.Relationships between the changes in
clinical outcomes
The relationships between the changes in clinical
outcomes are presented in Table 2. The changes in
health status assessed by the SGRQ and the CRQ
total scores weakly correlated with the changes in
%FEV1 and peak _VO2 (absolute correlation coeffi-
cients ½r ¼ 0:16 to 0.44, Po0:07). The change in
dyspnoea assessed by the MRC also significantly but
weakly correlated with the changes in %FEV1 and
peak _VO2 (r ¼ 0:37 and 0:35, Po0:05, respec-
tively). In comparison, changes in psychological
status assessed by the HADS did not significantly
correlate with changes in %FEV1 and peak _VO2,
except for a significant but weak correlation
between the HADS depression and %FEV1
ðr ¼ 0:26; P ¼ 0:0022Þ.
The relationships between the changes in health
status moderately correlated with the changes in
dyspnoea and the changes in psychological status
(absolute r ¼ 0.53–0.66, Po0:0001). The relation-
ship between the changes in dyspnoea and the
changes in psychological status was weak but
statistically significant (r ¼ 0:36 and 0.46,
Po0:0001).Comparisons between survivors and non-
survivors
In the present study, 25 study subjects died, 108
were alive at 5 years, and the living status of 4
subjects was unknown. Baseline data and annual
changes were compared between 108 survivors and
ARTICLE IN PRESS
30
32
34
36
38
40
42
44
46
48
50
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 0
SG
RQ
 to
tal
 sc
ore
(a) 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
4.5
4.6
4.7
4.8
4.9
5.0
5.1
5.2
5.3
5.4
5.5
5.6
CR
Q 
tot
al 
sco
re
(b)
0.7
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
M
R
C
(c)
3
4
5
6
7
H
A
D
S 
an
xi
et
y
(d) 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
3
4
5
6
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
H
A
D
S 
de
pr
es
sio
n
(e)
42
43
44
45
46
47
48
49
50
51
52
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
FE
V 1
 
(%
pre
dic
ted
)
(f)
Figure 1 Longitudinal changes in the SGRQ (a), the CRQ (b), the MRC (c), the anxiety (d) and depression (e) of the
HADS, and postbronchodilator FEV1 (f) in 45 patients with COPD who had complete data sets with no missing data every
6 months over 5 years. Higher scores indicate worse status on the SGRQ, the MRC, and the HADS, and the opposite is
true on the CRQ.
Table 2 Correlation coefficients between annual changes in various clinical parameters.
Variable SGRQ total CRQ total MRC HADS anxiety HADS depression %FEV1 Peak _VO2
SGRQ total 1
CRQ total 0.77 1
MRC 0.59 0.53 1
HADS anxiety 0.55 0.64 0.36 1
HADS depression 0.56 0.66 0.46 0.80 1
%FEV1 0.44 0.33 0.37 0.12 0.26 1
Peak _VO2 0.20
 0.16 0.35 0.08 0.13 0.21 1
Statistically significant relationships (Po0.05).
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Table 3 Comparisons of baseline data and annual changes between the 108 survivors and 25 non-survivors.
Baseline data Annual changes (/year)
Characteristic Survivors Non-survivors Survivors Non-survivors
Age, years 68.070.6 72.771.5
SGRQ total 34.271.5 43.372.4 2.0070.19 1.3370.41
CRQ total 5.4570.09 5.1770.14 0.1370.01 0.1070.02
MRC 0.970.1 1.670.1 0.1470.01 0.1470.02
HADS anxiety 4.370.3 5.770.8 0.1670.04 0.1370.06
HADS depression 3.770.3 4.270.7 0.1770.04 0.1570.06
FEV1, %pred 47.871.4 35.972.8
 0.970.1 0.770.2
Peak _VO2 ; mL/min/kg 15.570.3 11.570.6
 0.670.0 0.470.1
Data are presented as mean7SE.
Statistically significant differences between survivors and non-survivors (Po0.01).
Changes in patient reported outcomes in COPD 15125 non-survivors in Table 3. Regarding the baseline
data, non-survivors were significantly older and
worse as rated by the SGRQ and MRC scores, FEV1
levels and peak _VO2 : However, there were no
significant differences between annual changes in
outcomes between survivors and non-survivors.Discussion
We followed 5–year longitudinal changes in patient
reported outcomes versus physiological outcomes
in patients with COPD. We demonstrated that both
types of outcomes deteriorated significantly over
time, and deteriorations only weakly correlated
with one another.
Although COPD has its primary effect in the
lungs, structural and functional changes also take
place in other organs, which causes multisystem
symptoms.2 Therefore, COPD is regarded as a
systemic disorder, and a multidimensional assess-
ment is needed. However, the progression and
patterns of multiple COPD measurements over time
have not been followed simultaneously. We demon-
strated that although deteriorations in physiologi-
cal outcomes as evaluated by pulmonary function
and exercise capacity were confirmed,7 patient
reported outcomes as evaluated by health status,
dyspnoea and psychological status also deterio-
rated significantly and these deteriorations only
weakly correlated to physiological deteriorations.
This indicates that patient follow up with FEV1
alone leads to overlooking deteriorations in patient
reported outcomes, and it scientifically shows the
deteriorative characteristics of COPD.
Although health status deterioration in COPD
over 3 years has been previously demonstrated
using the SGRQ23 or the CRQ,9 to our knowledge,this is the longest study to follow it over 5 years.
The present study shows that health status con-
tinues to deteriorate over time, and tends to be
steep after 3 years as shown in Fig. 1. Although
COPD patients could maintain their health status by
using additionally bronchodilators or changing their
lifestyle at first, they may gradually begin to
become unable to adapt themselves to worsening
situations.
We evaluated health status using the most widely
used disease-specific instruments of the SGRQ and
the CRQ to compare responsiveness. Health status
measurements generally possess 3 properties24; a
discriminative property, an evaluative property and
a predictive property. We previously reported that
although both had similar discriminative proper-
ties,3 the SGRQ had a stronger ability to predict
mortality.25 Regarding responsiveness, although 3
rehabilitation studies26–28 reported conflicting re-
sults, the present study indicates that the SGRQ
and the CRQ were similarly responsive, judging
from the effect size and the standardized response
of the mean, except for the SGRQ symptom
component.
Dyspnoea is an important outcome in COPD,
because it is the most frequent symptom that COPD
patients complain about, and it is strongly related
to mortality.29,30 However, its longitudinal change
has rarely been analyzed. Mahler et al.31 demon-
strated that while pulmonary function improved in
patients with COPD, their dyspnoea score worsened
over 2 years. Lareau et al.32 showed that although
34 COPD patients experienced varying degrees of
airflow limitation over 5 years, their dyspnoea
scores did not differ from the beginning to the end
of the study. We demonstrated a deterioration in
dyspnoea with a larger sample size and a longer
observational period. In addition, weak correla-
tions between changes in dyspnoea and declines in
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that worsening dyspnoea may also be affected by
deteriorations in other important factors such as
cardiovascular fitness or muscular weakness.
Therefore, although measuring dyspnoea is recom-
mended as an indicator of disease severity in recent
guidelines,33,34 its longitudinal follow-up is also
necessary.
Psychological problems such as anxiety and
depression are common in patients with COPD
although they are not often addressed.35 Although
we demonstrated significant deteriorations in these
psychological indices over time, they were less
prominent than health status or dyspnoea dete-
riorations as shown in Fig. 1. A greater variability in
psychological status changes among patients may
exist judging from the large SE values as compared
to the means. Therefore, it is important to find
patients who show a faster deterioration in
psychological status, as anxiety and depression
are reported to be related to frequent hospitaliza-
tion for acute exacerbations36 or the outcomes of
emergency treatment in COPD,37 and their progres-
sion may inhibit the patient’s ability to manage the
disease in itself.
Unexpectedly, we did not find significant differ-
ences in annual changes in clinical outcomes
between survivors and non-survivors. This may be
partly because non-survivors already had a signifi-
cantly worse status in airflow limitation, exercise
capacity, health status and dyspnoea than survi-
vors. In addition, the aforementioned result reveals
that even outcomes in survivors deteriorated long-
itudinally in patients with COPD. Although we
anticipated that non-survivors had steeper declines
in clinical measurements, worse baseline data
seemed to have contributed more to the mortality
in the present study. This theme should be studied
in the future.
Recently, the MCID is an important emerging
concept in addition to the statistically significant
difference. Regarding some commonly used out-
come measures, the MCID has begun to suggest;
100mL on FEV1, 10W on maximal exercise tests,
and so on.38 Although, considering the MCID
ideology, the SGRQ reached the MCID faster than
the CRQ in the present study, MCID values represent
only empirically derived estimates,39 and it is
difficult to compare one MCID with another. How
to reach a common interpretation across the
different MCID on some outcomes is a problem that
needs to be resolved.
Some limitations of this study should be dis-
cussed. Firstly, the present study did not investi-
gate longitudinal changes in healthy subjects.
Therefore, although it is difficult to evaluate therelative deteriorations of these outcomes, one
should pay attention to relationships between
these changes. Secondly, we did not count the
number of exacerbations during the study period,
and therefore we could not evaluate their impact
on clinical outcomes although frequent exacerba-
tions have been reported to be related to health
status and other COPD parameters.40,41
In conclusion, we demonstrated that patient
reported outcomes as well as physiological out-
comes deteriorated over time in patients with
COPD, and scientifically cleared the deteriorative
characteristics of COPD. In addition, correlations
between both types of outcomes were relatively
weak. To capture the overall deterioration of COPD
from the perspective of patients and physicians,
these outcomes should be followed separately and
with caution.Acknowledgments
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